Association between SNPs of Circulating Vascular Endothelial Growth Factor Levels, Hypercholesterolemia and Metabolic Syndrome
Abstract
:1. Introduction
2. Materials and Methods
2.1. Ethics Statement
2.2. Study Population
2.3. Clinical and Biological Data Collection
2.4. Statistical Analysis
2.5. Meta-Analysis with Metabolic Syndrome
3. Results
4. Discussion
5. Conclusions
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Karr, S. Epidemiology and management of hyperlipidemia. Am. J. Manag. Care 2017, 23, 139. [Google Scholar]
- Gordon, T.; Castelli, W.P.; Hjortland, M.C.; Kannel, W.B.; Dawber, T.R. High density lipoprotein as a protective factor against coronary heart disease. Am. J. Med. 1977, 62, 707–714. [Google Scholar] [CrossRef]
- Ferrara, N.; Gerber, H.-P.; LeCouter, J. The biology of VEGF and its receptors. Nat. Med. 2003, 9, 669–676. [Google Scholar] [CrossRef] [PubMed]
- Ylä-Herttuala, S.; Rissanen, T.T.; Vajanto, I.; Hartikainen, J. Vascular endothelial growth factors: Biology and current status of clinical applications in cardiovascular medicine. J. Am. Coll. Cardiol. 2007, 49, 1015–1026. [Google Scholar] [CrossRef] [PubMed]
- Moulton, K.S.; Vakili, K.; Zurakowski, D.; Soliman, M.; Butterfield, C.; Sylvin, E.; Lo, K.-M.; Gillies, S.; Javaherian, K.; Folkman, J. Inhibition of plaque neovascularization reduces macrophage accumulation and progression of advanced atherosclerosis. Proc. Natl. Acad. Sci. USA 2003, 100, 4736–4741. [Google Scholar] [CrossRef] [Green Version]
- Kucukardali, Y.; Aydogdu, S.; Ozmen, N.; Yonem, A.; Solmazgul, E.; Ozyurt, M.; Cingozbay, Y.; Aydogdu, A. The relationship between severity of coronary artery disease and plasma level of vascular endothelial growth factor. Cardiovasc. Revascularization Med. 2008, 9, 66–70. [Google Scholar] [CrossRef]
- Blann, A.D.; Belgore, F.M.; Constans, J.; Conri, C.; Lip, G.Y. Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate. Am. J. Cardiol. 2001, 87, 1160–1163. [Google Scholar] [CrossRef]
- Eaton, C.B.; Gramling, R.; Parker, D.R.; Roberts, M.B.; Lu, B.; Ridker, P.M. Prospective association of vascular endothelial growth factor-A (VEGF-A) with coronary heart disease mortality in Southeastern New England. Atherosclerosis 2008, 200, 221–227. [Google Scholar] [CrossRef]
- Berrahmoune, H.; Herbeth, B.; Lamont, J.V.; Masson, C.; Fitzgerald, P.S.; Visvikis-Siest, S.; Visvikis-Siest, S. Heritability for Plasma VEGF Concentration in the Stanislas Family Study. Ann. Hum. Genet. 2007, 71, 54–63. [Google Scholar] [CrossRef]
- Debette, S.; Chen, M.H.; Destefano, A.; Choi, S.H.; Yang, Q.; Vasan, R.S.; Seshadri, S.; Visvikis-Siest, S.; Nezhad, M.A.; Marteau, J.B.; et al. Identification of cis-and trans-acting genetic variants explaining up to half the variation in circulating vascular endothelial growth factor levels. Circ. Res. 2011, 109, 554–563. [Google Scholar] [CrossRef]
- Stathopoulou, M.G.; Bonnefond, A.; Ndiaye, N.C.; Azimi-Nezhad, M.; El Shamieh, S.; Saleh, A.; Rancier, M.; Siest, G.; Lamont, J.; Fitzgerald, P.; et al. A common variant highly associated with plasma VEGFA levels also contributes to the variation of both LDL-C and HDL-C. J. Lipid Res. 2013, 54, 535–541. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Azimi-Nezhad, M.; Mirhafez, S.R.; Stathopoulou, M.G.; Murray, H.; Ndiaye, N.C.; Bahrami, A.; Varasteh, A.; Avan, A.; Bonnefond, A.; Rancier, M.; et al. The relationship between vascular endothelial growth factor cis- and trans-acting genetic variants and metabolic syndrome. Am. J. Med Sci. 2018, 355, 559–565. [Google Scholar] [CrossRef] [PubMed]
- Assaad, S.; Costanian, C.; Jaffal, L.; Tannous, F.; Stathopoulou, M.G.; El Shamieh, S. Association of TLR4 Polymorphisms, Expression, and Vitamin D with Helicobacter pylori Infection. J. Pers. Med. 2019, 9, 2. [Google Scholar] [CrossRef] [PubMed]
- Alghalyini, B.; El Shamieh, S.; Salami, A.; Siest, S.V.; Fakhoury, H.M.; Fakhoury, R. Effect of SLCO1B1 gene polymorphisms and vitamin D on statin-induced myopathy. Drug Metab. Pers. Ther. 2018, 33, 41–47. [Google Scholar] [CrossRef] [PubMed]
- El Shamieh, S.; Costanian, C.; Kassir, R.; Visvkis-Siest, S.; Bissar-Tadmouri, N.; Siest, S.V. APOE genotypes in Lebanon: Distribution and association with hypercholesterolemia and Alzheimer’s disease. Pers. Med. 2019, 16, 15–23. [Google Scholar] [CrossRef] [PubMed]
- Higgins, J.P.T.; Thompson, S.G.; Deeks, J.J.; Altman, D.G. Measuring inconsistency in meta-analyses. Br. Med. J. 2003, 327, 557–560. [Google Scholar] [CrossRef] [Green Version]
- Carroll, M.D.; Fryar, C.D.; Nguyen, D.T. Total and High-density lipoprotein cholesterol in adults: United States, 2015–2016. NCHS Data Brief 2017, 1–8. [Google Scholar]
- Gill, R.M.; Khan, S.A.; Jackson, R.T.; Duane, M. Prevalence of the Metabolic Syndrome in Central and South American Immigrant Residents of the Washington, DC, Area. J. Nutr. Metab. 2017, 2017, 9531964. [Google Scholar] [CrossRef]
- Sibai, A.-M.; Obeid, O.; Batal, M.; Adra, N.; El Khoury, D.; Hwalla, N. Prevalence and correlates of metabolic syndrome in an adult Lebanese population. CVD Prev. Control. 2008, 3, 83–90. [Google Scholar] [CrossRef]
- Gundogan, K.; Bayram, F.; Capak, M.; Tanriverdi, F.; Karaman, A.; Ozturk, A.; Altunbas, H.; Gokce, C.; Kalkan, A.; Yazici, C. Prevalence of metabolic syndrome in the Mediterranean region of Turkey: Evaluation of hypertension, diabetes mellitus, obesity, and dyslipidemia. Metab. Syndr. Relat. Disord. 2009, 7, 427–434. [Google Scholar] [CrossRef]
- Al-Lawati, J.A.; Mohammed, A.J.; Al-Hinai, H.Q.; Jousilahti, P. Prevalence of the Metabolic Syndrome Among Omani Adults. Diabet. Care 2003, 26, 1781–1785. [Google Scholar] [CrossRef] [Green Version]
- Ostovar, R.; Kiani, F.; Sayehmiri, F.; Yasemi, M.; Mohsenzadeh, Y.; Mohsenzadeh, Y. Prevalence of metabolic syndrome in Iran: A meta-analysis. Electron. Physician 2017, 9, 5402–5418. [Google Scholar] [CrossRef] [Green Version]
- Kivelä, A.M.; Heinonen, S.E.; Huusko, J.; Dijkstra, M.H.; Gurzeler, E.; Mäkinen, P.I.; Leppänen, P.; Olkkonen, V.M.; Eriksson, U.; Jauhiainen, M.; et al. The effects of VEGF-A on atherosclerosis, lipoprotein profile, and lipoprotein lipase in hyperlipidaemic mouse models. Cardiovasc. Res. 2013, 99, 716–723. [Google Scholar] [Green Version]
- Clerc, O.; Nanchen, D.; Cornuz, J.; Marques-Vidal, P.; Gmel, G.; Daeppen, J.-B.; Paccaud, F.; Mooser, V.; Waeber, G.; Vollenweider, P.; et al. Alcohol drinking, the metabolic syndrome and diabetes in a population with high mean alcohol consumption. Diabet. Med. 2010, 27, 1241–1249. [Google Scholar] [CrossRef]
- Corrao, G.; Rubbiati, L.; Bagnardi, V.; Zambon, A.; Poikolainen, K. Alcohol and coronary heart disease: A meta-analysis. Addict. 2000, 95, 1505–1523. [Google Scholar] [CrossRef]
- Meister, K.A.; Whelan, E.M.; Kava, R. The Health effects of moderate alcohol intake in humans: An epidemiologic review. Crit. Rev. Clin. Lab. Sci. 2000, 37, 261–296. [Google Scholar] [CrossRef]
- Park, H.; Kim, K. Association of alcohol consumption with lipid profile in hypertensive men. Alcohol Alcohol. 2012, 47, 282–287. [Google Scholar] [CrossRef]
Characteristics | Participants (n = 460) |
---|---|
Age | 40.60 ± 14.16 |
Gender n (%) | |
Male | 168 (36.5) |
Female | 292 (63.5) |
Education Level n (%) | |
None | 3 (0.7) |
School | 194 (42.2) |
University | 263 (57.2) |
Marital Status n (%) | |
Single | 121 (26.3) |
Married | 321 (69.8) |
Divorced | 18 (3.9) |
Characteristics | Participants (n = 460) |
---|---|
BMI (Kg/m2) | 25.71 ± 4.98 |
Alcohol consumption (current drinker) n (%) | 162 (35.3) |
Smoker n (%) | 122 (26.5) |
Physical activity (more than once per week) n (%) | 115 (25.0) |
Total cholesterol (mg/dL) | 181.41 ± 40.94 |
High n (%) | 351 (76.3) |
LDL-cholesterol (mg/dL) | 117.39 ± 33.52 |
High n (%) | 347 (75.4) |
HDL-cholesterol (mg/dL) | 45.53 ± 14.61 |
Low n (%) | 270 (58.7) |
Triglycerides (mg/dL) | 145.96 ± 124.34 |
High n (%) | 174 (37.8) |
SBP (mmHg) | 132.07 ± 15.89 |
DBP (mmHg) | 67.82 ± 9.12 |
Hypertension n (%) | 255 (55.4) |
MAF | |
rs6921438G > A | 0.34 |
rs4416670C > T | 0.49 |
rs6993770A > T | 0.34 |
rs10738760A > G | 0.46 |
Variables | SNP | Ancestral Alleles | MAF | p | Beta | SE | Trait |
---|---|---|---|---|---|---|---|
Age | <0.001 | 0.68 | 0.15 | Tchol | |||
<0.001 | 2.07 | 0.45 | HDL-C | ||||
<0.001 | 0.53 | 0.13 | LDL-C | ||||
Gender | <0.001 | 14.10 | 4.49 | Tchol | |||
<0.001 | 5.93 | 1.56 | HDL-C | ||||
<0.001 | 11.15 | 3.75 | LDL-C | ||||
VLDLR-KCNV2 | rs10738760 | A | 0.46 | 0.01 | –5.53 | 2.62 | Tchol |
ZFPM2 | rs6993770 | A | 0.34 | 0.007 | 7.89 | 2.90 | Tchol |
0.01 | 6.20 | 2.42 | LDL-C | ||||
ZFPM2 | rs6993770 x Gender | A | 0.02 | 3.661 | 1.58 | Tchol | |
0.03 | 2.795 | 1.31 | LDL-C |
Risk Factors | Total Cholesterol | LDL-C | MetS | |||
---|---|---|---|---|---|---|
OR (95% C.I.) | p | OR (95% C.I.) | p | OR (95% C.I.) | p | |
Age | ||||||
<40 | 1 | 1 | 1 | |||
≥40 | 22.67 (9.70–53.02) | <0.001 | - | ns | - | ns |
Gender | ||||||
Male | 1 | 1 | 1 | |||
Female | - | ns | - | ns | - | ns |
BMI | ||||||
<25 | 1 | 1 | 1 | |||
25–29.9 | - | ns | - | ns | 2.44 (1.29–4.62) | 0.006 |
≥30 | 3.03 (1.16–7.92) | 0.02 | 2.78 (1.06–7.33) | 0.04 | - | ns |
Marital status | ||||||
Non-married | 1 | 1 | 1 | |||
Married | 0.16 (0.07–0.35) | <0.001 | - | ns | 0.54 (0.28–1.03) | 0.06 |
Divorced | - | ns | - | ns | - | ns |
Widowed | - | ns | - | ns | - | ns |
Smoking status | ||||||
Non smoker | 1 | 1 | 1 | |||
Past smoker | - | ns | - | ns | - | ns |
Current smoker | 2.24 (1.08–4.64) | 0.03 | - | ns | - | ns |
Alcohol consumption | ||||||
Non drinker | 1 | 1 | 1 | |||
Past drinker | 0.01 (0–0.07) | <0.001 | 0.01 (0.001–0.11) | <0.001 | - | ns |
Current drinker | 0.47 (0.25–0.88) | 0.01 | - | ns | - | ns |
Physical activity | 1 | |||||
<1 per week | 1 | 1 | ||||
1 per week | 0.291 (0.12–0.68) | 0.004 | 0.24 (0.10–0.58) | 0.001 | - | ns |
≥2 per week | - | ns | - | ns | - | ns |
rs6993770 AA | 1 | 1 | 1 | |||
AT | - | ns | - | ns | - | ns |
TT | 2.61 (0.94–7.19) | 0.01 | 4.30 (1.37–13.51) | 0.01 | - | ns |
rs10738760 AA | 1 | 1 | 1 | |||
GA | - | ns | - | ns | 2.10 (1.10–4.01) | 0.02 |
GG | - | ns | - | ns | - | ns |
© 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Salami, A.; El Shamieh, S. Association between SNPs of Circulating Vascular Endothelial Growth Factor Levels, Hypercholesterolemia and Metabolic Syndrome. Medicina 2019, 55, 464. https://doi.org/10.3390/medicina55080464
Salami A, El Shamieh S. Association between SNPs of Circulating Vascular Endothelial Growth Factor Levels, Hypercholesterolemia and Metabolic Syndrome. Medicina. 2019; 55(8):464. https://doi.org/10.3390/medicina55080464
Chicago/Turabian StyleSalami, Ali, and Said El Shamieh. 2019. "Association between SNPs of Circulating Vascular Endothelial Growth Factor Levels, Hypercholesterolemia and Metabolic Syndrome" Medicina 55, no. 8: 464. https://doi.org/10.3390/medicina55080464